0 items

in your cart
$0.00

Prescription Drug Search

Strengths available for Doryx:

Doryx 100mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Doryx:

  • Austria
  • Azerbaijan
  • Bahamas
  • Belarus
  • Belize
  • Bermuda
  • Bolivia
  • Colombia
  • Czech Republic
  • Dominican Republic
  • El Salvador
  • Fiji
  • Finland
  • Georgia
  • Grenada
  • Guadeloupe
  • Hong Kong
  • Iceland
  • India
  • Japan
  • Korea, Republic of
  • Latvia
  • Liechtenstein
  • Lithuania
  • Mauritius
  • Netherlands
  • Panama
  • Qatar
  • Romania
  • Saudi Arabia
  • Serbia
  • Seychelles
  • South Africa
  • Sweden
  • Trinidad and Tobago
  • Tunisia
  • Ukraine
  • United Kingdom, UK
  • United States, US
  • Vanuatu
View All Countries

Latest news releases on Doryx:

WCRX, Watson Pharma in Legal Tussle - Zacks.com

Following the adverse court ruling regarding Doryx 150 mg, Warner Chilcott trimmed its 2012 guidance. The company expects to earn in the range of $3.30-$3.40 per share (on an adjusted basis) on revenues between $2.4 billion and $2.5 billion. Earlier ...

Watson files for low-dose birth control generic - Marketwatch

Mylan Inc. (MYL) this month launched a generic version of its Doryx acne drug after winning the approval of a federal court weighing in on a dispute between the two companies. Shares of Warner Chilcott were recently off 16 cents to $20.01.

Mylan Raises 2012 Earnings Guidance - Yahoo Finance

Last week, Mylan had announced that it has launched the first generic equivalent of Mayne Pharma's Doryx (150 mg), which is marketed by Warner Chilcott (WCRX). The U.S. District Court for the District of New Jersey ruled against the patent ...

WCRX, Watson Pharma in Legal Tussle - Analyst Blog - Boston Globe

Following the adverse court ruling regarding Doryx 150 mg, Warner Chilcott trimmed its 2012 guidance. The company expects to earn in the range of $3.30-$3.40 per share (on an adjusted basis) on revenues between $2.4 billion and $2.5 billion.

Warner Chilcott Tops But Cuts View - Analyst Blog - NASDAQ

Moreover, reduced sales of dermatological product Doryx also hurt revenues in the reported quarter. Revenues, however, beat the Zacks Consensus Estimate of $651 million. Revenues from osteoporosis products declined 30.5% to $162 million.  Actonel sales ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK